Strategies To Streamline Next-Gen AOC & RDC Programs From Lead Candidate Design To Manufacture

Next-generation drug conjugates, like antibody-oligonucleotide conjugates (AOCs) and radionuclide-drug conjugates (RDCs), are becoming a focus for drug developers who want to look beyond traditional therapies.

These innovative treatments combine the targeting ability of antibodies with either genetic (AOCs) or radioactive (RDCs) payloads, which opens up new ways to treat diseases. While AOCs and RDCs may seem similar, their components, design, and development processes are very different.

Their complexity also presents new challenges for manufacturers and regulators. This makes the development strategy for these therapies just as critical as the scientific research itself.

Dr. Stephen Verespy, Senior Director of Scientific Operations, and Dr. Jeffrey Mocny, Vice President of Regulatory Strategy at Abzena, share how their teams approach the development of AOCs and RDCs, emphasizing that science, strategy, and structure must all align to advance these novel modalities.